# EVUSHELD REFERRAL FORM

Pharmacy HyVee SOLUTIONS

## PATIENT INFORMATION

| Last Name | First Name | DOB |
|---|---|---|
| Gender | Social Security # | Primary Language |
| Address | | |
| City | State | ZIP |
| Allergies | | |
| Phone | Height | Weight |

ICD-10 Code
☐ Code ____________ Qualifying diagnosis
☐ U09.9 Post-Covid condition unspecified

## PRESCRIBER INFORMATION

| Name of Contact Sending Referral | | Title |
|---|---|---|
| Preferred Contact Method (check one) ☐ Email ☐ Phone ☐ Fax | Referral Contact Email | |
| Office Phone | Office Fax | |
| Practice / Facility Name | | |
| Address | | |
| City | State | ZIP |
| Prescriber Name / Specialty | | |

## INSURANCE INFORMATION

| Insurance Provider | Plan ID # |
|---|---|
| Insured's Name | Relationship to Patient |

Eligible for Medicare (check one) ☐ Yes ☐ No — List Red, White & Blue Card #

If no insurance, list driver's license number and state of issue

**Please fax with order form: Current Medication List & Copy of Insurance Card**

## ELIGIBILITY

**Exclusion Criteria**: EVUSHELD is not authorized for use in individuals:

- For treatment of COVID-19
- For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2
- Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.
- In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.

**Inclusion Criteria**: Check all that apply

☐ For the pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARSCoV-2 and:

Who have moderate to severe immune compromise due to a medical condition such as cancer, untreated HIV, etc.. (not a complete list, see EUA for more)

Who receive immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination.

## MEDICATION ORDERS

***EVUSHELD may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., antiinfectives) Standing orders may not be used per the EUA.**

☐ ***EVUSHELD New One Time Dose:** EVUSHELD once 300mg tixagevimab IM and 300mg cilgavimab IM as separate IM injections

☐ ***EVUSHELD** Every 6 months: EVUSHELD once 300mg tixagevimab IM and 300mg cilgavimab IM as separate IM injections

(Per FDA recommendation June 2022)

☒ **Anaphylaxis Kit** per Amber Specialty Pharmacy Home Infusion anaphylaxis treatment protocol.

**Indicate vaccination status:**

☐ Unvaccinated ☐ Partially Vaccinated ☐ Fully Vaccinated ☐ Boosted

## Nursing Orders

Administer IM in two injections, Monitor patient for one hour post injection, follow Anaphylaxis protocol if necessary.

## SIGNATURE

Prescriber Signature ____________ Date ____________

Please Print Name ____________ NPI ____________

**Phone: 855.896.9254**
**Fax: 855.370.0086**

REV.06.13.22